Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Nature|January 17, 2020
Isolation of an archaeon at the prokaryote-eukaryote interfaceHiroyuki Imachi, Masaru K Nobu, Nozomi Nakahara, et al.
Respiratory Investigation|June 5, 2026
Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in JapanShiho Goda, Tadaaki Yamada, Yasuhiro Goto, et al.
Nature Communications|April 5, 2016
Microelectrode characterization of coral daytime interior pH and carbonate chemistryWei-Jun Cai, Yuening Ma, Brian M Hopkinson, et al.
Thoracic Cancer|June 30, 2025
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective StudyAyako Shiono, Hisao Imai, Kyoichi Kaira, et al.
BMC Pulmonary Medicine|May 19, 2026
Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung diseaseShiho Goda, Tadaaki Yamada, Yasuhiro Goto, et al.
NPJ Precision Oncology|January 26, 2023
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancerYuki Katayama, Tadaaki Yamada, Keiko Tanimura, et al.
Cancer Letters|February 11, 2024
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cellsKenji Morimoto, Tadaaki Yamada, Soichi Hirai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 4, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant CancersYuki Katayama, Tadaaki Yamada, Keiko Tanimura, et al.
NPJ Precision Oncology|April 2, 2026
AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancersMasaki Ishida, Tadaaki Yamada, Yuki Katayama, et al.
Diagnostics (Basel, Switzerland)|February 25, 2022
Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung CancerSatomi Tanaka, Junji Uchino, Takashi Yokoi, et al.
Pageof 5